Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis

BMC Cancer

Table 4 Association between MMP9 overexpression and survival in patients with breast cancer

Survival	Subgroup	No. of studies	No. of patients	I² (%)	P for heterogeneity	Pooled HR (95%CI)	P for effect size
DFS	Overall	6	1002	70.5	0.005	1.73 (0.99–3.01)	0.052
	Analysis model
	Univariate	6	1002	74.4	0.002	1.86 (1.05–3.31)	0.034
	Multivariate	3	573	56.7	0.100	2.73 (1.33–5.61)	0.006
OS	Overall	18	2687	24.7	0.164	1.52 (1.30–1.77)	< 0.001
	Ethnicity
	Caucasians	6	744	22.0	0.268	1.21 (0.81–1.80)	0.344
	Asians	12	1943	25.0	0.198	1.58 (1.34–1.86)	< 0.001
	IHC analysis standard
	Percentage	7	1178	2.8	0.404	1.85 (1.32–2.59)	< 0.001
	SI	9	1239	24.4	0.226	1.51 (1.26–1.80)	< 0.001
	Other cut-offs	2	270	0	0.703	0.72 (0.36–1.45)	0.359
	HR data
	Reported	14	2249	9.9	0.344	1.43 (1.21–1.67)	< 0.001
	Estimated	4	438	0	0.644	2.84 (1.71–4.73)	< 0.001
	Analysis model
	Univariate	14	2190	63.8	0.001	1.79 (1.24–2.59)	0.002
	Multivariate	9	1592	1.4	0.422	1.75 (1.37–2.22)	< 0.001
	Sample size
	> 150	8	1703	18.8	0.281	1.33 (1.10–1.61)	0.003
	≤150	10	984	0	0.494	1.97 (1.51–2.56)	< 0.001
	Cancer subtype
	IDC	6	934	43.3	0.116	1.37 (1.11–1.68)	0.003
	TNBC	4	590	0	0.933	1.88 (1.39–2.55)	< 0.001
RFS	Overall	5	1292	79.7	0.001	1.53 (0.73–3.18)	0.259

OS overall survival, DFS disease-free survival, RFS recurrence-free survival, IHC immunohistochemistry, IDC infiltrating ductal carcinoma, TNBC triple-negative breast cancer, SI staining index, HR hazard ratio

ISSN: 1471-2407